2006
Sustained GH Release
Teichman et al. · J Clin Endocrinol Metab
Reported extended GH and IGF-1 elevations following CJC-1295 with DAC.
First batch in testingCOA pending
About CJC-1295 (With DAC)
CJC-1295 with DAC is the drug-affinity-complex variant of the modified GHRH 1-29 analogue, carrying an N-terminally appended maleimidopropionic acid (MPA) linker designed to bind serum albumin in vivo.
The DAC modification was developed to extend circulating half-life relative to non-DAC GHRH analogues. Research interest centers on prolonged GH-pulse profiles, sustained-release pharmacokinetics, and chronic-administration studies in pre-clinical models.
Each lot is independently verified for purity (HPLC + ESI-MS) and endotoxin (LAL kinetic chromogenic) before listing.
Identity & Specifications
Sequence
YADAIFTQSYRKVLAQLSARKLLQDIMSR + DAC linker
Length
30 residues + maleimidopropionic acid linker
Formula
C₁₆₅H₂₆₉N₄₇O₄₆
Mol. weight
3645.21 g/mol
CAS
863288-34-0
PubChem
N/A
Purity (HPLC)
Pending
Endotoxin (LAL)
Pending
Certificate of Analysis
§ First batch in testing — results populate here once the first production lot clears independent third-party verification. The table below shows the acceptance criteria every lot must meet.
| Parameter | Method | Spec | Result |
|---|---|---|---|
| Identity | ESI-MS | Conforms | Pending |
| Purity | HPLC-UV 220 nm | ≥ 98.0% | Pending |
| Endotoxin | LAL kinetic | < 0.5 EU/mg | Pending |
| Water content | Karl Fischer | ≤ 6.0% | Pending |
| Appearance | Visual | White lyophilized cake | Pending |
Selected References
- Teichman SL, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295. J Clin Endocrinol Metab, 2006.
- Robinson C, et al. Drug Affinity Complex (DAC) technology for half-life extension. ConjuChem disclosures, 2005.
- Mayo KE, et al. Growth hormone-releasing hormone analogs. Recent Prog Horm Res, 1995.
- Frohman LA, Kineman RD. GHRH and pituitary biology. Endocrinology, 1999.
- Khorram O, et al. GHRH analogues: structure-activity. Trends Endocrinol Metab, 1997.
Recent Research Highlights
2005
Albumin Binding Strategy
Robinson et al.
Discussed DAC technology for serum-albumin conjugation in peptide therapeutics research.
—
Pre-clinical PK Studies
Various
Various studies on prolonged-action GHRH analogues.
—
Comparator to Non-DAC
Various
Frequently studied alongside the no-DAC variant for kinetic comparison.
⊕
3rd Party Tested
Independent lab
≥98%
HPLC Purity
+ ESI-MS
LAL
Endotoxin
LAL kinetic
§
Lot-traceable
In COA library
§ Research-Use Compliance
Laboratory research chemical / reagent — not a supplement or drug.
This compound is supplied by Crescent Bioresearch LLC for laboratory research and pre-clinical use only. It is not a drug, dietary supplement, food, or cosmetic, and has not been approved by the U.S. Food and Drug Administration for human or veterinary administration, diagnosis, treatment, or prevention of any condition.
The pharmacological, toxicological, and stability properties of this compound have not been fully studied. It must therefore be handled only by personnel trained in laboratory safety practices.
The purchaser bears sole responsibility for ensuring that all handling, storage, and intended use comply with applicable local, state, and federal regulations. Full terms are set out in the RUO Disclaimer and Terms of Service.
